drugset / Trial / NCT05896020
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies.
Timeline
- Start
- 2023-07-10
- Primary completion
- 2026-06-15
- Completion
- 2026-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |